Production (Stage)
Caris Life Sciences, Inc.
CAI
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Net Income | -102.58M | -111.03M | |||
| Total Depreciation and Amortization | 7.05M | 17.71M | |||
| Total Amortization of Deferred Charges | 1.95M | 1.59M | |||
| Total Other Non-Cash Items | 48.93M | 18.99M | |||
| Change in Net Operating Assets | 13.32M | -1.18M | |||
| Cash from Operations | -31.34M | -73.93M | |||
| Capital Expenditure | -2.69M | -1.74M | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | 61.38M | |||
| Cash from Investing | -2.69M | 59.64M | |||
| Total Debt Issued | -- | 199.98M | |||
| Total Debt Repaid | -22.00K | -80.00K | |||
| Issuance of Common Stock | 1.43M | 210.00K | |||
| Repurchase of Common Stock | -22.00K | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -105.00K | -- | |||
| Cash from Financing | 1.29M | 200.11M | |||
| Foreign Exchange rate Adjustments | 4.00K | 1.00K | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -32.74M | 185.82M | |||